mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases

Molecular Therapy

Volumn 27, Issue 4, 2019, Pages 757-772

  Maruggi, Giulietta ^a   Zhang, Cuiling ^b   Li, Junwei ^b   Ulmer, Jeffrey B ^a   Yu, Dong ^a  

^a GLAXOSMITHKLINE   (United States)

^b QINGDAO AGRICULTURAL UNIVERSITY   (China)

Author keywords

infectious diseases; RNA based vaccine; self amplifying mRNA; synthetic vaccine; vaccine on demand

Indexed keywords

LIPID; MACROGOL; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MESSENGER RNA; NANOPARTICLE; PATTERN RECOGNITION RECEPTOR; PLASMID DNA; RNA VACCINE; SMALL INTERFERING RNA; TOLL LIKE RECEPTOR; VIRUS VECTOR; CANCER VACCINE; RECOMBINANT VACCINE;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; CELL MATURATION; CELLULAR IMMUNITY; DENDRITIC CELL; DRUG DEVELOPMENT; GENE TECHNOLOGY; HUMAN; HUMORAL IMMUNITY; IMMUNOMODULATION; INFECTION; INFECTION CONTROL; INNATE IMMUNITY; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; RABIES; REVIEW; RNA SEQUENCE; RNA TRANSLATION; SEMLIKI FOREST VIRUS; SINDBIS VIRUS; STREPTOCOCCUS INFECTION; TRANSFORMATIVE TECHNOLOGY; VENEZUELAN EQUINE ENCEPHALITIS VIRUS; ZIKA FEVER; ANIMAL; CHEMISTRY; COMMUNICABLE DISEASE CONTROL; DRUG DELIVERY SYSTEM; GENETICS; PROCEDURES; VACCINATION;

ANIMALS; CANCER VACCINES; COMMUNICABLE DISEASE CONTROL; DRUG DELIVERY SYSTEMS; HUMANS; LIPIDS; NANOPARTICLES; RNA, MESSENGER; VACCINATION; VACCINES, SYNTHETIC;

EID: 85061801116     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1016/j.ymthe.2019.01.020     Document Type: Review

References (169)

1. Jenner, E., An Inquiry into the Causes and Effects of the Variolae Vaccinae, a Disease Discovered in Some of the Western Counties of England, Particularly Gloucestershire, and Known by the Name of the Cow Pox. 1978, Sampson Low.
2. Standaert, B., Rappuoli, R., Towards a more comprehensive approach for a total economic assessment of vaccines?: 1. The building blocks for a health economic assessment of vaccination. J. Mark. Access Health Policy, 5, 2017, 1335162.
3. Younger, D.S., Younger, A.P., Guttmacher, S., Childhood vaccination: implications for global and domestic public health. Neurol. Clin. 34 (2016), 1035–1047.
4. Plotkin, S.A., Plotkin, S.L., The development of vaccines: how the past led to the future. Nat. Rev. Microbiol. 9 (2011), 889–893.
5. Kazmin, D., Nakaya, H.I., Lee, E.K., Johnson, M.J., van der Most, R., van den Berg, R.A., Ballou, W.R., Jongert, E., Wille-Reece, U., Ockenhouse, C., et al. Systems analysis of protective immune responses to RTS,S malaria vaccination in humans. Proc. Natl. Acad. Sci. USA 114 (2017), 2425–2430.
6. Bloom, D.E., Black, S., Rappuoli, R., Emerging infectious diseases: a proactive approach. Proc. Natl. Acad. Sci. USA 114 (2017), 4055–4059.
7. Rauch, S., Jasny, E., Schmidt, K.E., Petsch, B., New vaccine technologies to combat outbreak situations. Front. Immunol., 9, 2018, 1963.
8. Liu, M.A., Immunologic basis of vaccine vectors. Immunity 33 (2010), 504–515.
9. Chen, N., Xia, P., Li, S., Zhang, T., Wang, T.T., Zhu, J., RNA sensors of the innate immune system and their detection of pathogens. IUBMB Life 69 (2017), 297–304.
10. Akira, S., Uematsu, S., Takeuchi, O., Pathogen recognition and innate immunity. Cell 124 (2006), 783–801.
11. DeFrancesco, L., The ‘anti-hype’ vaccine. Nat. Biotechnol. 35 (2017), 193–197.
12. Brito, L.A., Kommareddy, S., Maione, D., Uematsu, Y., Giovani, C., Berlanda Scorza, F., Otten, G.R., Yu, D., Mandl, C.W., Mason, P.W., et al. Self-amplifying mRNA vaccines. Adv. Genet. 89 (2015), 179–233.
13. Hekele, A., Bertholet, S., Archer, J., Gibson, D.G., Palladino, G., Brito, L.A., Otten, G.R., Brazzoli, M., Buccato, S., Bonci, A., et al. Rapidly produced SAM(®) vaccine against H7N9 influenza is immunogenic in mice. Emerg. Microbes Infect., 2, 2013, e52.
14. Pardi, N., Hogan, M.J., Pelc, R.S., Muramatsu, H., Andersen, H., DeMaso, C.R., Dowd, K.A., Sutherland, L.L., Scearce, R.M., Parks, R., et al. Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. Nature 543 (2017), 248–251.
15. Richner, J.M., Himansu, S., Dowd, K.A., Butler, S.L., Salazar, V., Fox, J.M., Julander, J.G., Tang, W.W., Shresta, S., Pierson, T.C., et al. Modified mRNA vaccines protect against Zika virus infection. Cell, 169, 2017, 176.
16. Ulmer, J.B., Mansoura, M.K., Geall, A.J., Vaccines ‘on demand’: science fiction or a future reality. Expert Opin. Drug Discov. 10 (2015), 101–106.
17. Wolff, J.A., Malone, R.W., Williams, P., Chong, W., Acsadi, G., Jani, A., Felgner, P.L., Direct gene transfer into mouse muscle in vivo. Science 247 (1990), 1465–1468.
18. Martinon, F., Krishnan, S., Lenzen, G., Magné R., Gomard, E., Guillet, J.G., Lévy, J.P., Meulien, P., Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA. Eur. J. Immunol. 23 (1993), 1719–1722.
19. Conry, R.M., LoBuglio, A.F., Wright, M., Sumerel, L., Pike, M.J., Johanning, F., Benjamin, R., Lu, D., Curiel, D.T., Characterization of a messenger RNA polynucleotide vaccine vector. Cancer Res. 55 (1995), 1397–1400.
20. Hoerr, I., Obst, R., Rammensee, H.G., Jung, G., In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. Eur. J. Immunol. 30 (2000), 1–7.
21. Maruggi, G., Chiarot, E., Giovani, C., Buccato, S., Bonacci, S., Frigimelica, E., Margarit, I., Geall, A., Bensi, G., Maione, D., Immunogenicity and protective efficacy induced by self-amplifying mRNA vaccines encoding bacterial antigens. Vaccine 35 (2017), 361–368.
22. Vabret, N., Bhardwaj, N., Greenbaum, B.D., Sequence-specific sensing of nucleic acids. Trends Immunol. 38 (2017), 53–65.
23. Liang, F., Lindgren, G., Lin, A., Thompson, E.A., Ols, S., Röhss, J., John, S., Hassett, K., Yuzhakov, O., Bahl, K., et al. Efficient targeting and activation of antigen-presenting cells in vivo after modified mRNA vaccine administration in rhesus macaques. Mol. Ther. 25 (2017), 2635–2647.
24. Pepini, T., Pulichino, A.M., Carsillo, T., Carlson, A.L., Sari-Sarraf, F., Ramsauer, K., Debasitis, J.C., Maruggi, G., Otten, G.R., Geall, A.J., et al. Induction of an IFN-mediated antiviral response by a self-amplifying RNA vaccine: implications for vaccine design. J. Immunol. 198 (2017), 4012–4024.
25. Edwards, D.K., Jasny, E., Yoon, H., Horscroft, N., Schanen, B., Geter, T., Fotin-Mleczek, M., Petsch, B., Wittman, V., Adjuvant effects of a sequence-engineered mRNA vaccine: translational profiling demonstrates similar human and murine innate response. J. Transl. Med., 15, 2017, 1.
26. Iwasaki, A., Medzhitov, R., Control of adaptive immunity by the innate immune system. Nat. Immunol. 16 (2015), 343–353.
27. Geall, A.J., Mandl, C.W., Ulmer, J.B., RNA: the new revolution in nucleic acid vaccines. Semin. Immunol. 25 (2013), 152–159.
28. Pardi, N., Muramatsu, H., Weissman, D., Karikó K., In vitro transcription of long RNA containing modified nucleosides. Methods Mol. Biol. 969 (2013), 29–42.
29. Martin, S.A., Moss, B., Modification of RNA by mRNA guanylyltransferase and mRNA (guanine-7-)methyltransferase from vaccinia virions. J. Biol. Chem. 250 (1975), 9330–9335.
30. Malone, R.W., Felgner, P.L., Verma, I.M., Cationic liposome-mediated RNA transfection. Proc. Natl. Acad. Sci. USA 86 (1989), 6077–6081.
31. Stepinski, J., Waddell, C., Stolarski, R., Darzynkiewicz, E., Rhoads, R.E., Synthesis and properties of mRNAs containing the novel “anti-reverse” cap analogs 7-methyl(3′-O-methyl)GpppG and 7-methyl (3′-deoxy)GpppG. RNA 7 (2001), 1486–1495.
32. Li, Y., Kiledjian, M., Regulation of mRNA decapping. Wiley Interdiscip. Rev. RNA 1 (2010), 253–265.
33. Marcotrigiano, J., Gingras, A.C., Sonenberg, N., Burley, S.K., Cocrystal structure of the messenger RNA 5′ cap-binding protein (eIF4E) bound to 7-methyl-GDP. Cell 89 (1997), 951–961.
34. Pascolo, S., Messenger RNA-based vaccines. Expert Opin. Biol. Ther. 4 (2004), 1285–1294.
35. Pascolo, S., Vaccination with messenger RNA (mRNA). Handb. Exp. Pharmacol. 183 (2008), 221–235.
36. Weissman, D., Pardi, N., Muramatsu, H., Karikó K., HPLC purification of in vitro transcribed long RNA. Methods Mol. Biol. 969 (2013), 43–54.
37. Mu, X., Greenwald, E., Ahmad, S., Hur, S., An origin of the immunogenicity of in vitro transcribed RNA. Nucleic Acids Res. 46 (2018), 5239–5249.
38. Karikó K., Muramatsu, H., Ludwig, J., Weissman, D., Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA. Nucleic Acids Res., 39, 2011, e142.
39. Foster, J.B., Choudhari, N., Perazzelli, J., Storm, J., Hofmann, T.J., Jain, P., Storm, P.B., Pardi, N., Weissman, D., Waanders, A.J., et al. Purification of mRNA encoding chimeric antigen receptor is critical for generation of a robust T-cell response. Hum. Gene Ther., 2018, 10.1089/hum.2018.145 Published online October 2, 2018.
40. Muralidhara, B.K., Baid, R., Bishop, S.M., Huang, M., Wang, W., Nema, S., Critical considerations for developing nucleic acid macromolecule based drug products. Drug Discov. Today 21 (2016), 430–444.
41. CureVac. (2017). CureVac announces groundbreaking of industrial-scale GMP production facility for RNA therapeutics. https://www.curevac.com/news/curevac-announces-groundbreaking-of-industrial-scale-gmp-production-facility-for-rna-therapeutics/.
42. Moderna. (2018). Moderna opens new manufacturing site for Norwood, MA. https://investors.modernatx.com/news-releases/news-release-details/moderna-opens-new-manufacturing-site-norwood-ma.
43. Ross, J., mRNA stability in mammalian cells. Microbiol. Rev. 59 (1995), 423–450.
44. Andries, O., Mc Cafferty, S., De Smedt, S.C., Weiss, R., Sanders, N.N., Kitada, T., N(1)-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice. J. Control. Release 217 (2015), 337–344.
45. Thess, A., Grund, S., Mui, B.L., Hope, M.J., Baumhof, P., Fotin-Mleczek, M., Schlake, T., Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals. Mol. Ther. 23 (2015), 1456–1464.
46. Pardi, N., Hogan, M.J., Naradikian, M.S., Parkhouse, K., Cain, D.W., Jones, L., Moody, M.A., Verkerke, H.P., Myles, A., Willis, E., et al. Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses. J. Exp. Med. 215 (2018), 1571–1588.
47. Chatterjee, S., Pal, J.K., Role of 5′- and 3′-untranslated regions of mRNAs in human diseases. Biol. Cell 101 (2009), 251–262.
48. Jansen, R.P., mRNA localization: message on the move. Nat. Rev. Mol. Cell Biol. 2 (2001), 247–256.
49. Bashirullah, A., Cooperstock, R.L., Lipshitz, H.D., Spatial and temporal control of RNA stability. Proc. Natl. Acad. Sci. USA 98 (2001), 7025–7028.
50. Gallie, D.R., The cap and poly(A) tail function synergistically to regulate mRNA translational efficiency. Genes Dev. 5 (1991), 2108–2116.
51. Lundstrom, K., Latest development on RNA-based drugs and vaccines. Future Sci. OA, 4, 2018, FSO300.
52. Sahin, U., Karikó K., Türeci, Ö., mRNA-based therapeutics—developing a new class of drugs. Nat. Rev. Drug Discov. 13 (2014), 759–780.
53. Mauro, V.P., Chappell, S.A., A critical analysis of codon optimization in human therapeutics. Trends Mol. Med. 20 (2014), 604–613.
54. Fåhraeus, R., Marin, M., Olivares-Illana, V., Whisper mutations: cryptic messages within the genetic code. Oncogene 35 (2016), 3753–3759.
55. Vogel, A.B., Lambert, L., Kinnear, E., Busse, D., Erbar, S., Reuter, K.C., Wicke, L., Perkovic, M., Beissert, T., Haas, H., et al. Self-amplifying RNA vaccines give equivalent protection against influenza to mRNA vaccines but at much lower doses. Mol. Ther. 26 (2018), 446–455.
56. Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B.L., Tam, Y.K., Madden, T.D., Hope, M.J., Weissman, D., Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes. J. Control. Release 217 (2015), 345–351.
57. Karikó K., Buckstein, M., Ni, H., Weissman, D., Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 23 (2005), 165–175.
58. Diebold, S.S., Kaisho, T., Hemmi, H., Akira, S., Reis e Sousa, C., Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 303 (2004), 1529–1531.
59. Pichlmair, A., Schulz, O., Tan, C.P., Rehwinkel, J., Kato, H., Takeuchi, O., Akira, S., Way, M., Schiavo, G., Reis e Sousa, C., Activation of MDA5 requires higher-order RNA structures generated during virus infection. J. Virol. 83 (2009), 10761–10769.
60. Nallagatla, S.R., Hwang, J., Toroney, R., Zheng, X., Cameron, C.E., Bevilacqua, P.C., 5′-Triphosphate-dependent activation of PKR by RNAs with short stem-loops. Science 318 (2007), 1455–1458.
61. Iavarone, C., O'hagan, D.T., Yu, D., Delahaye, N.F., Ulmer, J.B., Mechanism of action of mRNA-based vaccines. Expert Rev. Vaccines 16 (2017), 871–881.
62. De Beuckelaer, A., Pollard, C., Van Lint, S., Roose, K., Van Hoecke, L., Naessens, T., Udhayakumar, V.K., Smet, M., Sanders, N., Lienenklaus, S., et al. Type I interferons interfere with the capacity of mRNA lipoplex vaccines to elicit cytolytic T cell responses. Mol. Ther. 24 (2016), 2012–2020.
63. Hornung, V., Ellegast, J., Kim, S., Brzózka, K., Jung, A., Kato, H., Poeck, H., Akira, S., Conzelmann, K.K., Schlee, M., et al. 5′-Triphosphate RNA is the ligand for RIG-I. Science 314 (2006), 994–997.
64. Anderson, B.R., Muramatsu, H., Nallagatla, S.R., Bevilacqua, P.C., Sansing, L.H., Weissman, D., Karikó K., Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation. Nucleic Acids Res. 38 (2010), 5884–5892.
65. Nallagatla, S.R., Bevilacqua, P.C., Nucleoside modifications modulate activation of the protein kinase PKR in an RNA structure-specific manner. RNA 14 (2008), 1201–1213.
66. Anderson, B.R., Muramatsu, H., Jha, B.K., Silverman, R.H., Weissman, D., Karikó K., Nucleoside modifications in RNA limit activation of 2′-5′-oligoadenylate synthetase and increase resistance to cleavage by RNase L. Nucleic Acids Res. 39 (2011), 9329–9338.
67. Karikó K., Muramatsu, H., Welsh, F.A., Ludwig, J., Kato, H., Akira, S., Weissman, D., Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol. Ther. 16 (2008), 1833–1840.
68. Karikó K., Muramatsu, H., Keller, J.M., Weissman, D., Increased erythropoiesis in mice injected with submicrogram quantities of pseudouridine-containing mRNA encoding erythropoietin. Mol. Ther. 20 (2012), 948–953.
69. Svitkin, Y.V., Cheng, Y.M., Chakraborty, T., Presnyak, V., John, M., Sonenberg, N., N1-methyl-pseudouridine in mRNA enhances translation through eIF2α-dependent and independent mechanisms by increasing ribosome density. Nucleic Acids Res. 45 (2017), 6023–6036.
70. Pardi, N., Parkhouse, K., Kirkpatrick, E., McMahon, M., Zost, S.J., Mui, B.L., Tam, Y.K., Karikó K., Barbosa, C.J., Madden, T.D., et al. Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies. Nat. Commun., 9, 2018, 3361.
71. Bahl, K., Senn, J.J., Yuzhakov, O., Bulychev, A., Brito, L.A., Hassett, K.J., Laska, M.E., Smith, M., Almarsson, Ö., Thompson, J., et al. Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses. Mol. Ther. 25 (2017), 1316–1327.
72. Lutz, J., Lazzaro, S., Habbeddine, M., Schmidt, K.E., Baumhof, P., Mui, B.L., Tam, Y.K., Madden, T.D., Hope, M.J., Heidenreich, R., Fotin-Mleczek, M., Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines. NPJ Vaccines, 2, 2017, 29.
73. Petsch, B., Schnee, M., Vogel, A.B., Lange, E., Hoffmann, B., Voss, D., Schlake, T., Thess, A., Kallen, K.J., Stitz, L., Kramps, T., Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection. Nat. Biotechnol. 30 (2012), 1210–1216.
74. Kallen, K.J., Heidenreich, R., Schnee, M., Petsch, B., Schlake, T., Thess, A., Baumhof, P., Scheel, B., Koch, S.D., Fotin-Mleczek, M., A novel, disruptive vaccination technology: self-adjuvanted RNActive(®) vaccines. Hum. Vaccin. Immunother. 9 (2013), 2263–2276.
75. Alberer, M., Gnad-Vogt, U., Hong, H.S., Mehr, K.T., Backert, L., Finak, G., Gottardo, R., Bica, M.A., Garofano, A., Koch, S.D., et al. Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial. Lancet 390 (2017), 1511–1520.
76. Schnee, M., Vogel, A.B., Voss, D., Petsch, B., Baumhof, P., Kramps, T., Stitz, L., An mRNA vaccine encoding rabies virus glycoprotein induces protection against lethal infection in mice and correlates of protection in adult and newborn pigs. PLoS Negl. Trop. Dis., 10, 2016, e0004746.
77. Rauch, S., Lutz, J., Kowalczyk, A., Schlake, T., Heidenreich, R., RNActive® technology: generation and testing of stable and immunogenic mRNA vaccines. Methods Mol. Biol. 1499 (2017), 89–107.
78. Fotin-Mleczek, M., Duchardt, K.M., Lorenz, C., Pfeiffer, R., Ojkić-Zrna, S., Probst, J., Kallen, K.J., Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity. J. Immunother. 34 (2011), 1–15.
79. Kowalczyk, A., Doener, F., Zanzinger, K., Noth, J., Baumhof, P., Fotin-Mleczek, M., Heidenreich, R., Self-adjuvanted mRNA vaccines induce local innate immune responses that lead to a potent and boostable adaptive immunity. Vaccine 34 (2016), 3882–3893.
80. Loomis, K.H., Lindsay, K.E., Zurla, C., Bhosle, S.M., Vanover, D.A., Blanchard, E.L., Kirschman, J.L., Bellamkonda, R.V., Santangelo, P.J., In vitro transcribed mRNA vaccines with programmable stimulation of innate immunity. Bioconjug. Chem. 29 (2018), 3072–3083.
81. Tews, B.A., Meyers, G., Self-replicating RNA. Methods Mol. Biol. 1499 (2017), 15–35.
82. Lundstrom, K., Replicon RNA viral vectors as vaccines. Vaccines (Basel), 4, 2016, E39.
83. Ljungberg, K., Liljeström, P., Self-replicating alphavirus RNA vaccines. Expert Rev. Vaccines 14 (2015), 177–194.
84. Atkins, G.J., Fleeton, M.N., Sheahan, B.J., Therapeutic and prophylactic applications of alphavirus vectors. Expert Rev. Mol. Med., 10, 2008, e33.
85. Mühlebach, M.D., Vaccine platform recombinant measles virus. Virus Genes 53 (2017), 733–740.
86. Humphreys, I.R., Sebastian, S., Novel viral vectors in infectious diseases. Immunology 153 (2018), 1–9.
87. Strauss, J.H., Strauss, E.G., The alphaviruses: gene expression, replication, and evolution. Microbiol. Rev. 58 (1994), 491–562.
88. Rupp, J.C., Sokoloski, K.J., Gebhart, N.N., Hardy, R.W., Alphavirus RNA synthesis and non-structural protein functions. J. Gen. Virol. 96 (2015), 2483–2500.
89. Lemm, J.A., Rümenapf, T., Strauss, E.G., Strauss, J.H., Rice, C.M., Polypeptide requirements for assembly of functional Sindbis virus replication complexes: a model for the temporal regulation of minus- and plus-strand RNA synthesis. EMBO J. 13 (1994), 2925–2934.
90. LaPointe, A.T., Gebhart, N.N., Meller, M.E., Hardy, R.W., Sokoloski, K.J., The identification and characterization of Sindbis virus RNA:host protein interactions. J. Virol., 92, 2018 e02171-17.
91. Frolova, E.I., Gorchakov, R., Pereboeva, L., Atasheva, S., Frolov, I., Functional Sindbis virus replicative complexes are formed at the plasma membrane. J. Virol. 84 (2010), 11679–11695.
92. Lundstrom, K., Biology and application of alphaviruses in gene therapy. Gene Ther. 12:Suppl 1 (2005), S92–S97.
93. Sawicki, D.L., Kaariainen, L., Lambek, C., Gomatos, P.J., Mechanism for control of synthesis of Semliki Forest virus 26S and 42s RNA. J. Virol. 25 (1978), 19–27.
94. Keränen, S., Kääriäinen, L., Functional defects of RNA-negative temperature-sensitive mutants of Sindbis and Semliki Forest viruses. J. Virol. 32 (1979), 19–29.
95. Perri, S., Greer, C.E., Thudium, K., Doe, B., Legg, H., Liu, H., Romero, R.E., Tang, Z., Bin, Q., Dubensky, T.W. Jr., et al. An alphavirus replicon particle chimera derived from venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector. J. Virol. 77 (2003), 10394–10403.
96. Lundstrom, K., Alphavirus-based vaccines. Methods Mol. Biol. 1404 (2016), 313–328.
97. Bernstein, D.I., Reap, E.A., Katen, K., Watson, A., Smith, K., Norberg, P., Olmsted, R.A., Hoeper, A., Morris, J., Negri, S., et al. Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers. Vaccine 28 (2009), 484–493.
98. Wecker, M., Gilbert, P., Russell, N., Hural, J., Allen, M., Pensiero, M., Chulay, J., Chiu, Y.L., Abdool Karim, S.S., Burke, D.S. HVTN 040/059 Protocol Team, NIAID HIV Vaccine Trials Network. Phase I safety and immunogenicity evaluations of an alphavirus replicon HIV-1 subtype C gag vaccine in healthy HIV-1-uninfected adults. Clin. Vaccine Immunol. 19 (2012), 1651–1660.
99. Mogler, M.A., Kamrud, K.I., RNA-based viral vectors. Expert Rev. Vaccines 14 (2015), 283–312.
100. Liljeström, P., Garoff, H., A new generation of animal cell expression vectors based on the Semliki Forest virus replicon. Biotechnology (N. Y.) 9 (1991), 1356–1361.
101. Gardner, J.P., Frolov, I., Perri, S., Ji, Y., MacKichan, M.L., zur Megede, J., Chen, M., Belli, B.A., Driver, D.A., Sherrill, S., et al. Infection of human dendritic cells by a sindbis virus replicon vector is determined by a single amino acid substitution in the E2 glycoprotein. J. Virol. 74 (2000), 11849–11857.
102. MacDonald, G.H., Johnston, R.E., Role of dendritic cell targeting in Venezuelan equine encephalitis virus pathogenesis. J. Virol. 74 (2000), 914–922.
103. Nishimoto, K.P., Laust, A.K., Wang, K., Kamrud, K.I., Hubby, B., Smith, J.F., Nelson, E.L., Restricted and selective tropism of a Venezuelan equine encephalitis virus-derived replicon vector for human dendritic cells. Viral Immunol. 20 (2007), 88–104.
104. Tonkin, D.R., Whitmore, A., Johnston, R.E., Barro, M., Infected dendritic cells are sufficient to mediate the adjuvant activity generated by Venezuelan equine encephalitis virus replicon particles. Vaccine 30 (2012), 4532–4542.
105. Zhou, X., Berglund, P., Rhodes, G., Parker, S.E., Jondal, M., Liljeström, P., Self-replicating Semliki Forest virus RNA as recombinant vaccine. Vaccine 12 (1994), 1510–1514.
106. Fleeton, M.N., Chen, M., Berglund, P., Rhodes, G., Parker, S.E., Murphy, M., Atkins, G.J., Liljeström, P., Self-replicative RNA vaccines elicit protection against influenza A virus, respiratory syncytial virus, and a tickborne encephalitis virus. J. Infect. Dis. 183 (2001), 1395–1398.
107. Geall, A.J., Verma, A., Otten, G.R., Shaw, C.A., Hekele, A., Banerjee, K., Cu, Y., Beard, C.W., Brito, L.A., Krucker, T., et al. Nonviral delivery of self-amplifying RNA vaccines. Proc. Natl. Acad. Sci. USA 109 (2012), 14604–14609.
108. Brito, L.A., Chan, M., Shaw, C.A., Hekele, A., Carsillo, T., Schaefer, M., Archer, J., Seubert, A., Otten, G.R., Beard, C.W., et al. A cationic nanoemulsion for the delivery of next-generation RNA vaccines. Mol. Ther. 22 (2014), 2118–2129.
109. Leyman, B., Huysmans, H., Mc Cafferty, S., Combes, F., Cox, E., Devriendt, B., Sanders, N.N., Comparison of the expression kinetics and immunostimulatory activity of replicating mRNA, nonreplicating mRNA, and pDNA after intradermal electroporation in pigs. Mol. Pharm. 15 (2018), 377–384.
110. Kamrud, K.I., Custer, M., Dudek, J.M., Owens, G., Alterson, K.D., Lee, J.S., Groebner, J.L., Smith, J.F., Alphavirus replicon approach to promoterless analysis of IRES elements. Virology 360 (2007), 376–387.
111. Magini, D., Giovani, C., Mangiavacchi, S., Maccari, S., Cecchi, R., Ulmer, J.B., De Gregorio, E., Geall, A.J., Brazzoli, M., Bertholet, S., Self-amplifying mRNA vaccines expressing multiple conserved influenza antigens confer protection against homologous and heterosubtypic viral challenge. PLoS ONE, 11, 2016, e0161193.
112. Hua, Z., Hou, B., TLR signaling in B-cell development and activation. Cell. Mol. Immunol. 10 (2013), 103–106.
113. Maruggi, G., Shaw, C.A., Otten, G.R., Mason, P.W., Beard, C.W., Engineered alphavirus replicon vaccines based on known attenuated viral mutants show limited effects on immunogenicity. Virology 447 (2013), 254–264.
114. Pollard, C., Rejman, J., De Haes, W., Verrier, B., Van Gulck, E., Naessens, T., De Smedt, S., Bogaert, P., Grooten, J., Vanham, G., De Koker, S., Type I IFN counteracts the induction of antigen-specific immune responses by lipid-based delivery of mRNA vaccines. Mol. Ther. 21 (2013), 251–259.
115. Sheehan, K.C., Lai, K.S., Dunn, G.P., Bruce, A.T., Diamond, M.S., Heutel, J.D., Dungo-Arthur, C., Carrero, J.A., White, J.M., Hertzog, P.J., Schreiber, R.D., Blocking monoclonal antibodies specific for mouse IFN-alpha/beta receptor subunit 1 (IFNAR-1) from mice immunized by in vivo hydrodynamic transfection. J. Interferon Cytokine Res. 26 (2006), 804–819.
116. + T cell immunity to mRNA vaccines. Trends Mol. Med. 23 (2017), 216–226.
117. Beissert, T., Koste, L., Perkovic, M., Walzer, K.C., Erbar, S., Selmi, A., Diken, M., Kreiter, S., Türeci, Ö., Sahin, U., Improvement of in vivo expression of genes delivered by self-amplifying RNA using vaccinia virus immune evasion proteins. Hum. Gene Ther. 28 (2017), 1138–1146.
118. Gorchakov, R., Frolova, E., Williams, B.R., Rice, C.M., Frolov, I., PKR-dependent and -independent mechanisms are involved in translational shutoff during Sindbis virus infection. J. Virol. 78 (2004), 8455–8467.
119. Kim, Y.G., Baltabekova, A.Z., Zhiyenbay, E.E., Aksambayeva, A.S., Shagyrova, Z.S., Khannanov, R., Ramanculov, E.M., Shustov, A.V., Recombinant Vaccinia virus-coded interferon inhibitor B18R: expression, refolding and a use in a mammalian expression system with a RNA-vector. PLoS ONE, 12, 2017, e0189308.
120. Uematsu, Y., Vajdy, M., Lian, Y., Perri, S., Greer, C.E., Legg, H.S., Galli, G., Saletti, G., Otten, G.R., Rappuoli, R., et al. Lack of interference with immunogenicity of a chimeric alphavirus replicon particle-based influenza vaccine by preexisting antivector immunity. Clin. Vaccine Immunol. 19 (2012), 991–998.
121. Wen, Y., Monroe, J., Linton, C., Archer, J., Beard, C.W., Barnett, S.W., Palladino, G., Mason, P.W., Carfi, A., Lilja, A.E., Human cytomegalovirus gH/gL/UL128/UL130/UL131A complex elicits potently neutralizing antibodies in mice. Vaccine 32 (2014), 3796–3804.
122. McCullough, K.C., Bassi, I., Milona, P., Suter, R., Thomann-Harwood, L., Englezou, P., Démoulins, T., Ruggli, N., Self-replicating replicon-RNA delivery to dendritic cells by chitosan-nanoparticles for translation in vitro and in vivo. Mol. Ther. Nucleic Acids, 3, 2014, e173.
123. Démoulins, T., Milona, P., Englezou, P.C., Ebensen, T., Schulze, K., Suter, R., Pichon, C., Midoux, P., Guzmán, C.A., Ruggli, N., McCullough, K.C., Polyethylenimine-based polyplex delivery of self-replicating RNA vaccines. Nanomedicine (Lond.) 12 (2016), 711–722.
124. Houseley, J., Tollervey, D., The many pathways of RNA degradation. Cell 136 (2009), 763–776.
125. Tatiparti, K., Sau, S., Kashaw, S.K., Iyer, A.K., siRNA delivery strategies: a comprehensive review of recent developments. Nanomaterials (Basel), 7, 2017, E77.
126. Johannes, L., Lucchino, M., Current challenges in delivery and cytosolic translocation of therapeutic RNAs. Nucleic Acid Ther. 28 (2018), 178–193.
127. Stanton, M.G., Current status of messenger RNA delivery systems. Nucleic Acid Ther. 28 (2018), 158–165.
128. Hajj, K.A., Whitehead, K.A., Tools for translation: non-viral materials for therapeutic mRNA delivery. Nat. Rev. Mater., 2, 2017, 17056.
129. Li, B., Zhang, X., Dong, Y., Nanoscale platforms for messenger RNA delivery. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol., 1530, 2018, e1530.
130. Kanasty, R.L., Whitehead, K.A., Vegas, A.J., Anderson, D.G., Action and reaction: the biological response to siRNA and its delivery vehicles. Mol. Ther. 20 (2012), 513–524.
131. Cullis, P.R., Hope, M.J., Lipid nanoparticle systems for enabling gene therapies. Mol. Ther. 25 (2017), 1467–1475.
132. Alnylam Pharmaceuticals. (2018). Alnylam announces first-ever FDA approval of an RNAi therapeutic, ONPATTRO™ (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. http://investors.alnylam.com/news-releases/news-release-details/alnylam-announces-first-ever-fda-approval-rnai-therapeutic.
133. Gilleron, J., Querbes, W., Zeigerer, A., Borodovsky, A., Marsico, G., Schubert, U., Manygoats, K., Seifert, S., Andree, C., Stöter, M., et al. Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape. Nat. Biotechnol. 31 (2013), 638–646.
134. Heyes, J., Palmer, L., Bremner, K., MacLachlan, I., Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids. J. Control. Release 107 (2005), 276–287.
135. Patel, S., Ashwanikumar, N., Robinson, E., DuRoss, A., Sun, C., Murphy-Benenato, K.E., Mihai, C., Almarsson, Ö., Sahay, G., Boosting intracellular delivery of lipid nanoparticle-encapsulated mRNA. Nano Lett. 17 (2017), 5711–5718.
136. Sabnis, S., Kumarasinghe, E.S., Salerno, T., Mihai, C., Ketova, T., Senn, J.J., Lynn, A., Bulychev, A., McFadyen, I., Chan, J., et al. A novel amino lipid series for mRNA delivery: improved endosomal escape and sustained pharmacology and safety in non-human primates. Mol. Ther. 26 (2018), 1509–1519.
137. Bhosle, S.M., Loomis, K.H., Kirschman, J.L., Blanchard, E.L., Vanover, D.A., Zurla, C., Habrant, D., Edwards, D., Baumhof, P., Pitard, B., Santangelo, P.J., Unifying in vitro and in vivo IVT mRNA expression discrepancies in skeletal muscle via mechanotransduction. Biomaterials 159 (2018), 189–203.
138. Chahal, J.S., Khan, O.F., Cooper, C.L., McPartlan, J.S., Tsosie, J.K., Tilley, L.D., Sidik, S.M., Lourido, S., Langer, R., Bavari, S., et al. Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose. Proc. Natl. Acad. Sci. USA 113 (2016), E4133–E4142.
139. Chahal, J.S., Fang, T., Woodham, A.W., Khan, O.F., Ling, J., Anderson, D.G., Ploegh, H.L., An RNA nanoparticle vaccine against Zika virus elicits antibody and CD8+ T cell responses in a mouse model. Sci. Rep., 7, 2017, 252.
140. Bogers, W.M., Oostermeijer, H., Mooij, P., Koopman, G., Verschoor, E.J., Davis, D., Ulmer, J.B., Brito, L.A., Cu, Y., Banerjee, K., et al. Potent immune responses in rhesus macaques induced by nonviral delivery of a self-amplifying RNA vaccine expressing HIV type 1 envelope with a cationic nanoemulsion. J. Infect. Dis. 211 (2015), 947–955.
141. Baeza Garcia, A., Siu, E., Sun, T., Exler, V., Brito, L., Hekele, A., Otten, G., Augustijn, K., Janse, C.J., Ulmer, J.B., et al. Neutralization of the Plasmodium-encoded MIF ortholog confers protective immunity against malaria infection. Nat. Commun., 9, 2018, 2714.
142. Brazzoli, M., Magini, D., Bonci, A., Buccato, S., Giovani, C., Kratzer, R., Zurli, V., Mangiavacchi, S., Casini, D., Brito, L.M., et al. Induction of broad-based immunity and protective efficacy by self-amplifying mRNA vaccines encoding influenza virus hemagglutinin. J. Virol. 90 (2015), 332–344.
143. Lindgren, G., Ols, S., Liang, F., Thompson, E.A., Lin, A., Hellgren, F., Bahl, K., John, S., Yuzhakov, O., Hassett, K.J., et al. Induction of robust B cell responses after influenza mRNA vaccination is accompanied by circulating hemagglutinin-specific ICOS+ PD-1+ CXCR3+ T follicular helper cells. Front. Immunol., 8, 2017, 1539.
144. Englezou, P.C., Sapet, C., Démoulins, T., Milona, P., Ebensen, T., Schulze, K., Guzman, C.A., Poulhes, F., Zelphati, O., Ruggli, N., McCullough, K.C., Self-amplifying replicon RNA delivery to dendritic cells by cationic lipids. Mol. Ther. Nucleic Acids 12 (2018), 118–134.
145. Benteyn, D., Heirman, C., Bonehill, A., Thielemans, K., Breckpot, K., mRNA-based dendritic cell vaccines. Expert Rev. Vaccines 14 (2015), 161–176.
146. Gornati, L., Zanoni, I., Granucci, F., Dendritic cells in the cross hair for the generation of tailored vaccines. Front. Immunol., 9, 2018, 1484.
147. Jones, K.L., Drane, D., Gowans, E.J., Long-term storage of DNA-free RNA for use in vaccine studies. Biotechniques 43 (2007), 675–681.
148. Stitz, L., Vogel, A., Schnee, M., Voss, D., Rauch, S., Mutzke, T., Ketterer, T., Kramps, T., Petsch, B., A thermostable messenger RNA based vaccine against rabies. PLoS Negl. Trop. Dis., 11, 2017, e0006108.
149. Grunwitz, C., Kranz, L.M., mRNA cancer vaccines—messages that prevail. Curr. Top. Microbiol. Immunol. 405 (2017), 145–164.
150. Kaczmarek, J.C., Kowalski, P.S., Anderson, D.G., Advances in the delivery of RNA therapeutics: from concept to clinical reality. Genome Med., 9, 2017, 60.
151. Fiedler, K., Lazzaro, S., Lutz, J., Rauch, S., Heidenreich, R., mRNA cancer vaccines. Recent Results Cancer Res. 209 (2016), 61–85.
152. Pastor, F., Berraondo, P., Etxeberria, I., Frederick, J., Sahin, U., Gilboa, E., Melero, I., An RNA toolbox for cancer immunotherapy. Nat. Rev. Drug Discov. 17 (2018), 751–767.
153. Krammer, F., Palese, P., Advances in the development of influenza virus vaccines. Nat. Rev. Drug Discov. 14 (2015), 167–182.
154. Scorza, F.B., Pardi, N., New kids on the block: RNA-based influenza virus vaccines. Vaccines (Basel), 6, 2018, E20.
155. Kranz, L.M., Diken, M., Haas, H., Kreiter, S., Loquai, C., Reuter, K.C., Meng, M., Fritz, D., Vascotto, F., Hefesha, H., et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature 534 (2016), 396–401.
156. Crotty, S., Follicular helper CD4 T cells (TFH). Annu. Rev. Immunol. 29 (2011), 621–663.
157. Suan, D., Sundling, C., Brink, R., Plasma cell and memory B cell differentiation from the germinal center. Curr. Opin. Immunol. 45 (2017), 97–102.
158. Pilkinton, M.A., Nicholas, K.J., Warren, C.M., Smith, R.M., Yoder, S.M., Talbot, H.K., Kalams, S.A., Greater activation of peripheral T follicular helper cells following high dose influenza vaccine in older adults forecasts seroconversion. Vaccine 35 (2017), 329–336.
159. Krammer, F., Palese, P., Influenza virus hemagglutinin stalk-based antibodies and vaccines. Curr. Opin. Virol. 3 (2013), 521–530.
160. CureVac. (2018). CureVac announces first study participant enrolled in phase I clinical trial testing prophylactic mRNA. https://www.curevac.com/newsroom/news/curevac-announces-first-study-participant-enrolled-in-phase-i-clinical-trial-testing-prophylactic-mr/.
161. Richner, J.M., Jagger, B.W., Shan, C., Fontes, C.R., Dowd, K.A., Cao, B., Himansu, S., Caine, E.A., Nunes, B.T.D., Medeiros, D.B.A., et al. Vaccine mediated protection against Zika virus-induced congenital disease. Cell 170 (2017), 273–283.e12.
162. Erasmus, J.H., Khandhar, A.P., Guderian, J., Granger, B., Archer, J., Archer, M., Gage, E., Fuerte-Stone, J., Larson, E., Lin, S., et al. A nanostructured lipid carrier for delivery of a replicating viral RNA provides single, low-dose protection against Zika. Mol. Ther. 26 (2018), 2507–2522.
163. John, S., Yuzhakov, O., Woods, A., Deterling, J., Hassett, K., Shaw, C.A., Ciaramella, G., Multi-antigenic human cytomegalovirus mRNA vaccines that elicit potent humoral and cell-mediated immunity. Vaccine 36 (2018), 1689–1699.
164. Fischer, S., Gerriets, T., Wessels, C., Walberer, M., Kostin, S., Stolz, E., Zheleva, K., Hocke, A., Hippenstiel, S., Preissner, K.T., Extracellular RNA mediates endothelial-cell permeability via vascular endothelial growth factor. Blood 110 (2007), 2457–2465.
165. Kannemeier, C., Shibamiya, A., Nakazawa, F., Trusheim, H., Ruppert, C., Markart, P., Song, Y., Tzima, E., Kennerknecht, E., Niepmann, M., et al. Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation. Proc. Natl. Acad. Sci. USA 104 (2007), 6388–6393.
166. Zhu, Z., Gorman, M.J., McKenzie, L.D., Chai, J.N., Hubert, C.G., Prager, B.C., Fernandez, E., Richner, J.M., Zhang, R., Shan, C., et al. Correction: Zika virus has oncolytic activity against glioblastoma stem cells. J. Exp. Med., 214, 2017, 3145.
167. Meyer, M., Huang, E., Yuzhakov, O., Ramanathan, P., Ciaramella, G., Bukreyev, A., Modified mRNA-based vaccines elicit robust immune responses and protect guinea pigs from Ebola virus disease. J. Infect. Dis. 217 (2018), 451–455.
168. Zhao, M., Li, M., Zhang, Z., Gong, T., Sun, X., Induction of HIV-1 gag specific immune responses by cationic micelles mediated delivery of gag mRNA. Drug Deliv. 23 (2016), 2596–2607.
169. Pardi, N., Hogan, M.J., Porter, F.W., Weissman, D., mRNA vaccines—a new era in vaccinology. Nat. Rev. Drug Discov. 17 (2018), 261–279.